Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 381

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study

Open access
Witkowski, Benoit, Duru, Valentine, Khim, Nimol, Ross, Leila S, Saintpierre, Benjamin, Beghain, Johann, Chy, Sophy, Kim, Saorin, Ke, Sopheakvatey, Kloeung, Nimol, Eam, Rotha, Khean, Chanra, Ken, Malen, Loch, Kaknika, Bouillon, Anthony, Domergue, Anais, Ma, Laurence, Bouchier, Christiane, Leang, Rithea, Huy, Rekol, Nuel, Grégory, Barale, Jean-Christophe, Legrand, Eric, Ringwald, Pascal, Fidock, David A, Mercereau-Puijalon, Odile, Ariey, Frédéric, Ménard, Didier·2017·The Lancet Infectious Diseases

Abstract

BACKGROUND: Western Cambodia is the epicentre of Plasmodium falciparum multidrug resistance and is facing high rates of dihydroartemisinin-piperaquine treatment failures. Genetic tools to detect the multidrug-resistant parasites are needed. Artemisinin resistance can be tracked using the K13 molecular marker, but no marker exists for piperaquine resistance. We aimed to identify genetic markers of piperaquine resistance and study their association with dihydroartemisinin-piperaquine treatment failures. METHODS: We obtained blood samples from Cambodian patients infected with P falciparum and treated with dihydroartemisinin-piperaquine. Patients were followed up for 42 days during the years 2009-15. We established in-vitro and ex-vivo susceptibility profiles for a subset using piperaquine survival assays. We determined whole-genome sequences by Illumina paired-reads sequencing, copy number variations by qPCR, RNA concentrations by qRT-PCR, and protein concentrations by immunoblotting. Fisher's exact and non-parametric Wilcoxon rank-sum tests were used to identify significant differences in single-nucleotide polymorphisms or copy number variants, respectively, for differential distribution between piperaquine-resistant and piperaquine-sensitive parasite lines. FINDINGS: Whole-genome exon sequence analysis of 31 culture-adapted parasite lines associated amplification of the plasmepsin 2-plasmepsin 3 gene cluster with in-vitro piperaquine resistance. Ex-vivo piperaquine survival assay profiles of 134 isolates correlated with plasmepsin 2 gene copy number. In 725 patients treated with dihydroartemisinin-piperaquine, multicopy plasmepsin 2 in the sample collected before treatment was associated with an adjusted hazard ratio (aHR) for treatment failure of 20·4 (95% CI 9·1-45·5, p<0·0001). Multicopy plasmepsin 2 predicted dihydroartemisinin-piperaquine failures with 0·94 (95% CI 0·88-0·98) sensitivity and 0·77 (0·74-0·81) specificity. Analysis of samples collected across the country from 2002 to 2015 showed that the geographical and temporal increase of the proportion of multicopy plasmepsin 2 parasites was highly correlated with increasing dihydroartemisinin-piperaquine treatment failure rates (r=0·89 [95% CI 0·77-0·95], p<0·0001, Spearman's coefficient of rank correlation). Dihydroartemisinin-piperaquine efficacy at day 42 fell below 90% when the proportion of multicopy plasmepsin 2 parasites exceeded 22%. INTERPRETATION: Piperaquine resistance in Cambodia is strongly associated with amplification of plasmepsin 2-3, encoding haemoglobin-digesting proteases, regardless of the location. Multicopy plasmepsin 2 constitutes a surrogate molecular marker to track piperaquine resistance. A molecular toolkit combining plasmepsin 2 with K13 and mdr1 monitoring should provide timely information for antimalarial treatment and containment policies. FUNDING: Institut Pasteur in Cambodia, Institut Pasteur Paris, National Institutes of Health, WHO, Agence Nationale de la Recherche, Investissement d'Avenir programme, Laboratoire d'Excellence Integrative "Biology of Emerging Infectious Diseases".

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(16)30415-7

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 381

Metadata

Authors
Witkowski, B., Duru, V., Khim, N., Ross, L. S., Saintpierre, B., Beghain, J., Chy, S., Kim, S., Ke, S., Kloeung, N., Eam, R., Khean, C., Ken, M., Loch, K., Bouillon, A., Domergue, A., Ma, L., Bouchier, C., Leang, R., Huy, R., Nuel, G., Barale, J.-C., Legrand, E., Ringwald, P., Fidock, D. A., Mercereau-Puijalon, O., Ariey, F., & Ménard, D.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2017-02
Volume
17
Issue
2
Pages
174-183
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2547295550
Cited by
381
References
22
FWCI
41.11
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study. https://app.cochat.ai/papers/10.1016/s1473-3099(16)30415-7
The paper
Witkowski, B., Duru, V., Khim, N., Ross, L. S., Saintpierre, B., Beghain, J., Chy, S., Kim, S., Ke, S., Kloeung, N., Eam, R., Khean, C., Ken, M., Loch, K., Bouillon, A., Domergue, A., Ma, L., Bouchier, C., Leang, R., . . . Ménard, D. (2017). A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(16)30415-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.